Company profile
ACHIEVE LIFE SCIENCES, INC.
NASDAQ:ACHVBiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| APATORSEN SODIUM | phase2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (31)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01497470 | phase1 | completed | 2012-04-01 | 2013-07-01 | Achieve Life Sciences | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen |
| NCT01630733 | phase3 | completed | 2012-10-24 | 2016-11-17 | Achieve Life Sciences | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer |
| NCT03303911 | phase1_2 | terminated | 2017-10-06 | 2018-10-05 | Achieve Life Sciences | A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers |
| NCT01454089 | phase2 | completed | 2011-10-01 | 2014-11-01 | Achieve Life Sciences | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer |
| NCT05206370 | phase3 | completed | 2022-01-20 | 2023-03-21 | Achieve Life Sciences | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers |
FDA applications (0)
No records yet.